Skip to main content
Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

Featuring Thomas Powles, MBBS, MD

 

Thomas Powles, MBBS, MD, Barts Cancer Institute at Queen Mary University of London, United Kingdom, discusses results from the phase 3 LITESPARK-005 study, which compared patient reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Results indicated that patients treated with belzutifan experienced prolonged time to deterioration and greater quality of life compared to those treated with everolimus.


Source:

Powles T, Albiges L, Jalkanen KJ, et al. Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study. Presented at the 2024 ASCO GU Cancers Symposium; January 25-27, 2024; San Francisco, California. Abstract 361

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.